Halozyme Therapeutics (HALO) Tops Q2 EPS by 11c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $98.49 -2.17%
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Net income (loss): -28.95M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of $0.02, $0.11 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $43.4 million versus the consensus estimate of $25.12 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
